Oppenheimer Issues Pessimistic Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

BridgeBio Pharma (NASDAQ:BBIO) had its target price decreased by equities researchers at Oppenheimer from $83.00 to $81.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 23.35% from the company’s current price.

Other research analysts also recently issued reports about the company. The Goldman Sachs Group lifted their target price on BridgeBio Pharma from $55.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Piper Sandler lifted their price objective on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Cantor Fitzgerald upped their price objective on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. TD Cowen restated a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Finally, Barclays initiated coverage on shares of BridgeBio Pharma in a research note on Wednesday, January 28th. They set an “overweight” rating on the stock. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $82.50.

BridgeBio Pharma Stock Down 3.9%

NASDAQ:BBIO traded down $2.65 during trading hours on Wednesday, reaching $65.67. 2,480,744 shares of the company’s stock were exchanged, compared to its average volume of 3,267,873. BridgeBio Pharma has a 1-year low of $28.33 and a 1-year high of $84.94. The firm has a market capitalization of $12.65 billion, a price-to-earnings ratio of -15.75 and a beta of 1.13. The company has a 50-day moving average of $75.24 and a 200 day moving average of $64.53.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The firm had revenue of $154.18 million for the quarter, compared to analyst estimates of $150.71 million. During the same period last year, the firm earned ($1.40) earnings per share. The business’s revenue was up 2521.2% on a year-over-year basis. Research analysts forecast that BridgeBio Pharma will post -3.67 EPS for the current fiscal year.

Insider Activity at BridgeBio Pharma

In related news, CEO Neil Kumar sold 28,053 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $71.39, for a total value of $2,002,703.67. Following the sale, the chief executive officer owned 234,451 shares in the company, valued at $16,737,456.89. This represents a 10.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Randal W. Scott sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total value of $754,600.00. Following the completion of the transaction, the director directly owned 11,589 shares of the company’s stock, valued at $874,505.94. The trade was a 46.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 204,174 shares of company stock worth $15,012,335 over the last three months. 18.20% of the stock is currently owned by company insiders.

Institutional Trading of BridgeBio Pharma

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of BridgeBio Pharma by 2.1% in the third quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock valued at $874,257,000 after buying an additional 347,074 shares in the last quarter. Janus Henderson Group PLC grew its stake in BridgeBio Pharma by 25.8% in the 4th quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock valued at $841,349,000 after acquiring an additional 2,259,378 shares during the last quarter. Farallon Capital Management LLC increased its holdings in BridgeBio Pharma by 9.8% during the 4th quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock valued at $688,292,000 after acquiring an additional 806,463 shares in the last quarter. Aisling Capital Management LP increased its holdings in BridgeBio Pharma by 0.4% during the 3rd quarter. Aisling Capital Management LP now owns 6,089,611 shares of the company’s stock valued at $316,294,000 after acquiring an additional 21,486 shares in the last quarter. Finally, Invesco Ltd. raised its position in BridgeBio Pharma by 23.0% during the fourth quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock worth $369,547,000 after acquiring an additional 902,648 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Morgan Stanley raised its price target to $98 and kept an “overweight” rating, implying roughly ~47% upside vs. the current price — a clear buy-side signal that can support the stock. Benzinga
• Positive Sentiment: BridgeBio reported Q4 revenue of $154.2M vs. ~$150.7M expected and revenue was up ~2,521% year‑over‑year — evidence of commercial traction (Attruby was highlighted in the company release), which reduces near‑term execution risk. GlobeNewswire
• Positive Sentiment: Several Wall Street shops have been raising targets recently (Cantor Fitzgerald, HC Wainwright, Goldman and others noted), which can attract momentum buyers and support higher valuations. MarketBeat analyst roundup
• Neutral Sentiment: Full Q4 earnings call/transcripts are available — useful for details on Attruby uptake, guidance and pipeline timelines; these may provide follow‑up catalysts but are informational until new guidance or data appear. Yahoo Finance transcript
• Negative Sentiment: BridgeBio missed on EPS: reported a ($1.00) loss vs. ($0.75) expected — the wider-than-expected loss is pressuring near-term sentiment despite the revenue beat. Zacks
• Negative Sentiment: CEO Neil Kumar sold 28,053 shares (recently part of several sales), a sizable insider disposition that can raise short-term investor caution even if filings show he retains a large stake. InsiderTrades / SEC filing

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.